Active	Status	Sponsor type	Region	Phase	Filter
4 Active 15 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Skolnik, Jeffrey
NCT04398433: INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)	Completed	1/2	32	US	INO-3107, CELLECTRA™ 2000	Inovio Pharmaceuticals	Respiratory Papillomatosis	12/22	12/22
NCT03502785 / 2018-000309-21: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma	Active, not recruiting	1/2	35	US	INO-5401, INO-9012, Atezolizumab, CELLECTRA™ 2000	Inovio Pharmaceuticals	Urothelial Carcinoma	12/25	12/25
NCT03491683: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) From trial in combination with INO-5401 & INO-9012 for 1L GBM Nov 2019 - Nov 2019: From trial in combination with INO-5401 & INO-9012 for 1L GBM	Active, not recruiting	1/2	52	US	INO-5401, INO-9012, Cemiplimab, REGN2810, Radiation Therapy, Temozolomide	Inovio Pharmaceuticals	Glioblastoma	12/25	12/25
Sylvester, Donna
T4G RCT, NCT04702373: Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT	Active, not recruiting	3	144	Canada, US	passive range of motion exercise therapy	Carelon Research, National Heart, Lung, and Blood Institute (NHLBI)	Congenital Heart Disease	11/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Skolnik, Jeffrey
NCT04398433: INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)	Completed	1/2	32	US	INO-3107, CELLECTRA™ 2000	Inovio Pharmaceuticals	Respiratory Papillomatosis	12/22	12/22
NCT03502785 / 2018-000309-21: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma	Active, not recruiting	1/2	35	US	INO-5401, INO-9012, Atezolizumab, CELLECTRA™ 2000	Inovio Pharmaceuticals	Urothelial Carcinoma	12/25	12/25
NCT03491683: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) From trial in combination with INO-5401 & INO-9012 for 1L GBM Nov 2019 - Nov 2019: From trial in combination with INO-5401 & INO-9012 for 1L GBM	Active, not recruiting	1/2	52	US	INO-5401, INO-9012, Cemiplimab, REGN2810, Radiation Therapy, Temozolomide	Inovio Pharmaceuticals	Glioblastoma	12/25	12/25
Sylvester, Donna
T4G RCT, NCT04702373: Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT	Active, not recruiting	3	144	Canada, US	passive range of motion exercise therapy	Carelon Research, National Heart, Lung, and Blood Institute (NHLBI)	Congenital Heart Disease	11/24	12/24